Список литературы к Главе 5

32. Oakes C.C., Claus R., Gu L. et al. Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia // Cancer Discov. 2014. Vol. 4, N 3. P. 348–3461.

33. Landau D.A., Clement K., Ziller M.J. et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia // Cancer Cell. 2014. Vol. 26, N 6. P. 813-825.

34. Lawrence M.S., Stojanov P., Mermel C.H. et al. Discovery and saturation analysis of cancer genes across 21 tumour types // Nature. 2014. Vol. 505, N 7484. P. 495–501.

35. Haferlach C., Dicker F., Weiss T. et al. Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters // Genes Chromosomes Cancer. 2010. Vol. 49, N 9. P. 851–859.

36. Rossi D., Rasi S., Fabbri G. et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia // Blood. 2012. Vol. 119, N 2. P. 521–529.

37. Cortese D., Sutton L.A., Cahill N. et al. On the way towards a «CLL prognostic index»: focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort // Leukemia. 2014. Vol. 28, N 3. P. 710–713.

38. Rossi D., Khiabanian H., Spina V. et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia // Blood. 2014. Vol. 123, N 14. P. 2139–2147.

39. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data // Lancet Oncol. 2016. Vol. 17, N 6. P. 779–790.

40. Nadeu F., Delgado J., Royo C. et al. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia // Blood. 2016. Vol. 127, N 17. P. 2122–2130.

41. Rossi D., Rasi S., Spina V. et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia // Blood. 2013. Vol. 121, N 8. P. 1403–1412.

42. Jeromin S., Weissmann S., Haferlach C. et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients // Leukemia. 2014. Vol. 28, N 1. P. 108–117.

43. Baliakas P., Hadzidimitriou A., Sutton L.A. et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia // Leukemia. 2015. Vol. 29, N 2. P. 329–336.

44. Rossi D., Cerri M., Deambrogi C. et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness // Clin. Cancer Res. 2009. Vol. 15, N 3. P. 995–1004.

45. Hallek M., Cheson B.D., Catovsky D. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL // Blood. 2018. Vol. 131, N 25. P. 2745–2760.

46. Roberts A.W., Davids M.S., Pagel J.M. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2016. Vol. 374, N 4. P. 311–322.

47. Byrd J.C., Furman R.R., Coutre S.E. et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib // Blood. 2015. Vol. 125, N 16. P. 2497–2506.

48. Amin N.A., Malek S.N. Gene mutations in chronic lymphocytic leukemia // Semin. Oncol. 2016. Vol. 43, N 2. P. 215–221.

49. Rossi D., Terzi-di-Bergamo L., De Paoli L. et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia // Blood. 2015. Vol. 126, N 16. P. 1921–1924.

50. Thompson P.A., Tam C.S., O’Brien S.M. et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia // Blood. 2016. Vol. 127, N 3. P. 303–309.

51. Fischer K., Bahlo J., Fink A.M. et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial // Blood. 2016. Vol. 127, N 2. P. 208–215.

52. Stilgenbauer S., Schnaiter A., Paschka P. et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial // Blood. 2014. Vol. 123, N 21. P. 3247–3254.

53. Austen B., Powell J.E., Alvi A. et al. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL // Blood. 2005. Vol. 106, N 9. P. 3175–3182.

54. Ouillette P., Li J., Shaknovich R. et al. Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia // Genes Chromosomes Cancer. 2012. Vol. 51, N 12. P. 1125–1132.

55. Austen B., Skowronska A., Baker C. et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion // J. Clin. Oncol. 2007. Vol. 25, N 34. P. 5448–5457.

56. Skowronska A., Parker A., Ahmed G. et al. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial // J. Clin. Oncol. 2012. Vol. 30, N 36. P. 4524–4532.

57. Del Giudice I., Rossi D., Chiaretti S. et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL // Haematologica. 2012. Vol. 97, N 3. P. 437–441.

58. López C., Delgado J., Costa D. et al. Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations // Genes Chromosomes Cancer. 2012. Vol. 51, N 9. P. 881–889.

59. Bittolo T., Pozzo F., Bomben R. et al. Mutations in the 3' untranslated region of NOTCH1 are associated with low CD20 expression levels chronic lymphocytic leukemia // Haematologica. 2017. Vol. 102, N 8. P. e305–e309.

60. Tausch E., Beck P., Schlenk R.F. et al. Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1 // Haematologica. 2020. Vol. 105, N 10. P. 2440–2447.

61. Close V., Close W., Kugler S.J. et al. FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL // Blood. 2019. Vol. 133, N 8. P. 830–839.

62. Falisi E., Novella E., Visco C. et al. B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities // Hematol. Oncol. 2014. Vol. 32, N 1. P. 22–30.

63. Fabbri G., Holmes A.B., Viganotti M. et al. Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia // Proc. Natl Acad. Sci. USA. 2017. Vol. 114, N 14. P. E2911–E2919.

64. Will C.L., Lührmann R. Spliceosome structure and function // Cold Spring Harb. Perspect. Biol. 2011. Vol. 3, N 7. Article ID a003707.

65. David C.J., Manley J.L. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged // Genes Dev. 2010. Vol. 24, N 21. P. 2343–2364.

66. Rossi D., Bruscaggin A., Spina V. et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness // Blood. 2011. Vol. 118, N 26. P. 6904–6908.

67. Rossi D., Fangazio M., Rasi S. et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia // Blood. 2012. Vol. 119, N 12. P. 2854–2862.

68. Rose-Zerilli M.J., Forster J., Parker H. et al. ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial // Haematologica. 2014. Vol. 99, N 4. P. 736–742.

69. Blakemore S.J., Clifford R., Parker H. et al. Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial // Leukemia. 2020. Vol. 34, N 7. P. 1760–1774.

70. Diop F., Moia R., Favini C. et al. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia // Haematologica. 2020. Vol. 105, N 2. P. 448–456.

71. Bonnert T.P., Garka K.E., Parnet P. et al. The cloning and characterization of human MyD88: a member of an IL-1 receptor related family // FEBS Lett. 1997. Vol. 402, N 1. P. 81–84.

72. Martínez-Trillos A., Pinyol M., Navarro A. et al. Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome // Blood. 2014. Vol. 123, N 24. P. 3790–3796.

73. Mullighan C.G., Phillips L.A., Su X. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia // Science. 2008. Vol. 322, N 5906. P. 1377–1380.

74. Gerlinger M., Rowan A.J., Horswell S. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing // N. Engl. J. Med. 2012. Vol. 366, N 10. P. 883–892.

75. Ouillette P., Saiya-Cork K., Seymour E. et al. Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia // Clin. Cancer Res. 2013. Vol. 19, N 11. P. 2893–2904.

76. Wang J., Khiabanian H., Rossi D. et al. Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia // Elife. 2014. Vol. 3. Article ID e02869.

77. Knight S.J., Yau C., Clifford R. et al. Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia // Leukemia. 2012. Vol. 26, N 7. P. 1564–1575.

78. Braggio E., Kay N.E., VanWier S. et al. Longitudinal genome-wide analysis of patients with chronic lymphocytic leukemia reveals complex evolution of clonal architecture at disease progression and at the time of relapse // Leukemia. 2012. Vol. 26, N 7. P. 1698–1701.

79. Schuh A., Becq J., Humphray S. et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns // Blood. 2012. Vol. 120, N 20. P. 4191–4196.

80. Gohil S.H., Wu C.J. Dissecting CLL through high-dimensional single-cell technologies // Blood. 2019. Vol. 133, N 13. P. 1446–1456.

81. Moia R., Patriarca A., Schipani M. et al. Precision medicine management of chronic lymphocytic leukemia // Cancers (Basel). 2020. Vol. 12, N 3. P. 642.